glp-1 market news november 2025 Ozempic Statistics: Weight Loss Medication Data GLP-1 Market Trends and Global

Existing DTC Prescribers

Recognizing the potential of semaglutide for weight management, researchers developed Wegovy, a higher-dose version of semaglutide approved in 2021 explicitly for chronic weight management in patients with obesity or overweight with at least one weight-related comorbidity

Its hard to think, if its 2030, and we have many of these medicines that weve proven the benefits for chronic diseases and the government said its worth it after this two-year pilot theyre doing its hard to think of too many employers who would say, Thats not for me, Ricks told me

And yet, Ive opted outnot because I feel sanctimonious about pursuing my weight-loss goals without medication (which I am), or because I think taking GLP-1s is somehow cheating or taking the easy way out (I dont, and its not), but because even though doctors have suggested I try the drugs, Im concerned about certain effects of a treatment thats only become mainstream for weight loss fairly recently

Each fills gaps the other cannot address alone